CL2016000154A1 - Composición para la gestión de las náuseas y los vómitos. - Google Patents

Composición para la gestión de las náuseas y los vómitos.

Info

Publication number
CL2016000154A1
CL2016000154A1 CL2016000154A CL2016000154A CL2016000154A1 CL 2016000154 A1 CL2016000154 A1 CL 2016000154A1 CL 2016000154 A CL2016000154 A CL 2016000154A CL 2016000154 A CL2016000154 A CL 2016000154A CL 2016000154 A1 CL2016000154 A1 CL 2016000154A1
Authority
CL
Chile
Prior art keywords
nausea
vomiting
management
composition
salt
Prior art date
Application number
CL2016000154A
Other languages
English (en)
Spanish (es)
Inventor
Manon Vranderick
Jean-Luc St-Onge
Michele Gallo
Éric Gervais
Original Assignee
Duchesnay Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50877783&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016000154(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Duchesnay Inc filed Critical Duchesnay Inc
Publication of CL2016000154A1 publication Critical patent/CL2016000154A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
CL2016000154A 2013-07-22 2016-01-21 Composición para la gestión de las náuseas y los vómitos. CL2016000154A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361856971P 2013-07-22 2013-07-22

Publications (1)

Publication Number Publication Date
CL2016000154A1 true CL2016000154A1 (es) 2016-08-05

Family

ID=50877783

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000154A CL2016000154A1 (es) 2013-07-22 2016-01-21 Composición para la gestión de las náuseas y los vómitos.

Country Status (28)

Country Link
US (3) US10028941B2 (enExample)
EP (1) EP3024466B1 (enExample)
JP (1) JP6379194B2 (enExample)
KR (1) KR102242391B1 (enExample)
CN (1) CN105492013B (enExample)
AR (1) AR097023A1 (enExample)
AU (1) AU2014295765B2 (enExample)
BR (1) BR112016001474A2 (enExample)
CA (1) CA2847022C (enExample)
CL (1) CL2016000154A1 (enExample)
CY (1) CY1120386T1 (enExample)
DK (1) DK3024466T3 (enExample)
EA (1) EA029690B1 (enExample)
ES (1) ES2670619T3 (enExample)
HU (1) HUE039131T2 (enExample)
IL (1) IL243638B (enExample)
MX (1) MX366760B (enExample)
MY (1) MY191347A (enExample)
NO (1) NO3086669T3 (enExample)
NZ (1) NZ716017A (enExample)
PL (1) PL3024466T3 (enExample)
PT (1) PT3024466T (enExample)
SA (1) SA516370443B1 (enExample)
SG (1) SG11201600122RA (enExample)
TW (2) TWI654977B (enExample)
UY (1) UY35674A (enExample)
WO (1) WO2015010194A1 (enExample)
ZA (1) ZA201600383B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104136004B (zh) 2012-02-22 2018-03-06 达切斯内公司 多西拉敏和吡哆醇和/或其代谢物或盐的制剂
ES2670619T3 (es) 2013-07-22 2018-05-31 Duchesnay Inc. Composición para la gestión de náuseas y vómitos
TWI595874B (zh) 2014-08-29 2017-08-21 達契斯奈股份有限公司 多西拉敏及吡哆醇及／或其代謝產物或鹽之多模式釋放調配物
US10244873B2 (en) 2015-10-01 2019-04-02 Isee Store Innovations, Llc Adjustable product display system and method

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
GB8524001D0 (en) 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
US4842867A (en) 1986-05-09 1989-06-27 Alza Corporation Pulsed drug delivery of doxylamine
IT1201136B (it) 1987-01-13 1989-01-27 Resa Farma Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive
US5110597A (en) 1987-06-25 1992-05-05 Alza Corporation Multi-unit delivery system
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5387421A (en) 1991-01-31 1995-02-07 Tsrl, Inc. Multi stage drug delivery system
NZ286242A (en) 1991-03-26 1997-11-24 Csl Ltd Use of veterinary implant as a single dose vaccination system: rupturable polymer film coating around core of active agent and water soluble excipient
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
DE19716732C2 (de) 1997-03-07 1999-03-25 Max Delbrueck Centrum Spezifische Magnetosomen, Verfahren zu ihrer Herstellung und ihre Verwendung
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US7744916B2 (en) 1997-06-11 2010-06-29 Umd, Inc. Coated vaginal device for delivery of anti-migraine and anti-nausea drugs
FR2772615B1 (fr) 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
JP2002541092A (ja) 1999-04-06 2002-12-03 ファーマクエスト・リミテッド メチルフェニデートのパルス性送達のための薬学的投薬形態
US6197329B1 (en) 1999-05-03 2001-03-06 Drugtech Corporation Anti-nausea compositions and methods
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
AU4305101A (en) 1999-11-22 2001-06-04 Research Foundation Of The State University Of New York, The Magnetic nanoparticles for selective therapy
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6500457B1 (en) 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
US6924273B2 (en) 2000-10-03 2005-08-02 Scott W. Pierce Chondroprotective/restorative compositions and methods of use thereof
CA2350195C (en) 2000-12-20 2003-06-10 Duchesnay Inc. Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate
CA2432438C (en) 2001-01-09 2011-04-26 Microchips, Inc. Flexible microchip devices for ophthalmic and other applications
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
US7704542B2 (en) * 2001-09-12 2010-04-27 Xanodyne Pharmaceuticals, Inc. Vitamin/mineral compositions with DHA
CA2392486A1 (en) 2002-07-05 2002-12-08 Duchesnay Inc. Pharmaceutical dosage form bearing pregnancy-friendly indicia
JP4436258B2 (ja) 2002-08-16 2010-03-24 マイクロチップス・インコーポレーテッド 制御された放出デバイスおよび方法
GB0229725D0 (en) 2002-12-19 2003-01-29 Univ Wales Medicine Haplotype partitioning and growth hormone SNPs
US20100221321A1 (en) 2003-02-27 2010-09-02 Innercap Technologies, Inc. Apparatus And Methods For Delivering A Plurality Of Medicaments For Management Of Co-Morbid Diseases, Illnesses Or Conditions
JP5107041B2 (ja) 2004-09-01 2012-12-26 マイクロチップス・インコーポレーテッド レザバ内容物の制御された放出または曝露のための、マルチキャップレザバデバイス
GB0502475D0 (en) 2005-02-07 2005-03-16 Sb Pharmco Inc Novel compositions
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US20070141147A1 (en) 2005-12-21 2007-06-21 Auriga Laboratories, Inc. Sequential release pharmaceutical formulations
US20090004281A1 (en) 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
KR101190708B1 (ko) 2010-03-12 2012-10-12 주식회사 대웅제약 모사프리드 또는 이의 염을 포함하는 서방형 약학 조성물
EP2555756B1 (en) 2010-04-07 2018-08-22 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
WO2011163206A2 (en) 2010-06-22 2011-12-29 Twi Pharmaceuticals, Inc. Controlled release compositions with reduced food effect
WO2012112437A1 (en) 2011-02-14 2012-08-23 The Procter & Gamble Company Filmcoated solid dosage forms comprising honey in the coating
EP2717860A4 (en) 2011-06-08 2014-11-05 Sti Pharma Llc FORMULATION FROM A WATER SOLUBLE AND PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND WITH CONTROLLED ABSORPTION FOR ONLY DAILY APPLICATION
CN104136004B (zh) 2012-02-22 2018-03-06 达切斯内公司 多西拉敏和吡哆醇和/或其代谢物或盐的制剂
WO2013123569A1 (en) 2012-02-22 2013-08-29 Duchesnay Inc. Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
ES2670619T3 (es) 2013-07-22 2018-05-31 Duchesnay Inc. Composición para la gestión de náuseas y vómitos

Also Published As

Publication number Publication date
CY1120386T1 (el) 2019-07-10
TWI654977B (zh) 2019-04-01
CA2847022C (en) 2015-04-07
UY35674A (es) 2014-12-31
TW201513860A (zh) 2015-04-16
US20150025033A1 (en) 2015-01-22
KR102242391B1 (ko) 2021-04-21
AR097023A1 (es) 2016-02-10
WO2015010194A1 (en) 2015-01-29
HK1218264A1 (en) 2017-02-10
TWI589292B (zh) 2017-07-01
EA201690149A1 (ru) 2016-06-30
ES2670619T3 (es) 2018-05-31
US20150025032A1 (en) 2015-01-22
PT3024466T (pt) 2018-07-13
US10028941B2 (en) 2018-07-24
EA029690B1 (ru) 2018-04-30
TW201720442A (zh) 2017-06-16
ZA201600383B (en) 2017-11-29
CN105492013B (zh) 2018-09-18
MX366760B (es) 2019-07-23
US9452181B2 (en) 2016-09-27
PL3024466T3 (pl) 2018-08-31
IL243638A0 (en) 2016-02-29
MY191347A (en) 2022-06-17
EP3024466A1 (en) 2016-06-01
SA516370443B1 (ar) 2018-08-08
EP3024466A4 (en) 2017-03-29
US20160143892A1 (en) 2016-05-26
BR112016001474A2 (pt) 2020-04-14
DK3024466T3 (en) 2018-06-06
AU2014295765B2 (en) 2019-02-14
KR20160033201A (ko) 2016-03-25
EP3024466B1 (en) 2018-04-04
NO3086669T3 (enExample) 2018-06-23
CA2847022A1 (en) 2014-06-03
IL243638B (en) 2019-09-26
JP6379194B2 (ja) 2018-08-22
AU2014295765A1 (en) 2016-02-04
NZ716017A (en) 2020-07-31
US9439920B2 (en) 2016-09-13
SG11201600122RA (en) 2016-02-26
HUE039131T2 (hu) 2018-12-28
CN105492013A (zh) 2016-04-13
JP2016527237A (ja) 2016-09-08
MX2016000884A (es) 2016-05-05

Similar Documents

Publication Publication Date Title
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
MX2017001512A (es) Compuestos activos hacia bromodominios.
CL2016000925A1 (es) Inhibidores de bromodominio
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
CL2015003280A1 (es) Derivados de benzimidazol como inhibidores de bromodominio
CU20170172A7 (es) 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos
CL2016001111A1 (es) Formulaciones de compuestos de azaindol.
CL2016001737A1 (es) Derivados heterocíclicos bicíclicos como inhibidores de bromodominio
SV2016005137A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
UY36275A (es) Compuestos aminopirimidinilo
CL2014002093A1 (es) Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
CL2015002060A1 (es) Compuestos.
MX2017000627A (es) Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
CL2015001377A1 (es) Inhbibidores de bmi-1 primidinas sustituidas inversas
BR112015023417A2 (pt) compostos heterocíclicos e seus usos
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
CL2018000007A1 (es) Compuestos inhibidores de la señalización de la vía de notch
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
UY36151A (es) ?una composición farmacéutica que comprende un inhibidor de fosfoinosítido 3-quinasa delta y un corticosteroide?.
CL2015003635A1 (es) Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos útiles como inhibidores de quinasa.
UY35354A (es) Combinaciones que comprenden compuestos maba y corticosteroides
CL2014001828A1 (es) Sistema de dosificacion oral de liberacion dual que comprende doxilamina y piridoxina y/o sus analogos, metabolitos y sales de los mismos; forma de dosificacion oral de liberacion dual; kit farmaceutico; uso para aliviar los sintomas de nauseas y vomitos, incluidos los del embarazo.